Current Synthetic and Systems Biology
ISSN: 2332-0737
OPEN ACCESS Freely available online

Perspective

Parasite-Powered Brain Therapies: Genetic Engineering's Role in Treating Alzheimer's and Parkinson’s

Jianhui Lammertyn*

Department of Microbiology, University of British Columbia, Nova Scotia, Canada

DESCRIPTION

In the ongoing quest to treat neurological diseases, scientists are analyzing new, innovative methods of delivering therapeutics directly into the brain. One of the most novel approaches is the use of genetically engineered parasites to carry treatments across the notoriously impermeable Blood-Brain Barrier (BBB). This breakthrough technology could revolutionize treatments for conditions such as Alzheimer's, Parkinson’s, and even certain types of brain cancer.

The blood-brain barrier challenge

The blood-brain barrier is a protective shield formed by tightly packed cells lining the blood vessels in the brain. This barrier is essential for maintaining brain health by blocking harmful substances from entering the brain, but it also complicates drug delivery. Traditional therapies, including those for neuro-degenerative diseases, struggle to cross the BBB, limiting their effectiveness. As a result, scientists have long sought innovative ways to breach this barrier without compromising brain safety.

Parasites as biological delivery vessels

Recent research has turned to genetically engineered parasites as potential "smugglers" of therapeutics. The idea is to exploit the unique biology of parasitic organisms, which have evolved the ability to cross biological barriers, including the BBB. These parasites are modified at the genetic level to transport drugs, genes, or other therapeutic agents directly into the brain.

One of the most promising candidates for this role is the Toxoplasma gondii parasite, which infects cats and can cross the BBB in humans. By harnessing the parasite's natural ability to invade brain cells, scientists are able to modify it to carry specific treatments. These treatments could range from neuroprotective compounds to gene therapies aimed at halting or reversing the damage caused by diseases like Alzheimer’s or Parkinson's.

Genetic engineering of parasites

The process of genetically modifying parasites involves several advanced techniques. Scientists isolate the parasite and modify its DNA to include the therapeutic cargo, often using CRISPR-Cas9 technology to ensure precise changes. The modified parasites are then introduced into the body, where they can migrate through the bloodstream and infiltrate the brain. Once inside, the parasites can release the therapeutic payload in a controlled manner, bypassing the BBB and ensuring direct delivery to the targeted regions of the brain.

The potential of this approach lies in its ability to transport a wide range of therapeutic molecules that would otherwise struggle to reach the brain. This includes small molecule drugs, biologics, RNA-based therapies, and even gene editing tools like CRISPR, which have shown promise in treating genetic disorders.

Overcoming challenges and ethical considerations

Despite the promise, there are significant hurdles to overcome in this research. One of the primary issues is the safety of using live, genetically modified organisms in humans. While the parasites are engineered to deliver therapeutics, they still pose the risk of unwanted side effects or unintended consequences. Rigorous testing and monitoring are required to ensure the treatments are both effective and safe.

Another consideration is the ethical implications of using genetically modified organisms, particularly parasites, in medical treatments. The idea of introducing a live organism into the body for therapeutic purposes raises questions about long-term effects, potential ecological impacts, and how these organisms are controlled after the therapeutic task is complete.

The future of parasite-based brain therapeutics

While still in the experimental stages, genetically engineered parasites hold enormous promise in the department of brain therapeutics. If successful, this approach could provide a new avenue for treating a range of neurological conditions that have long been difficult to address. In the near future, this technique could be applied to targeted gene therapies for genetic diseases, immunotherapies for brain cancer, and personalized treatments for neurodegenerative disorders.

Correspondence to: Jianhui Lammertyn, Department of Microbiology, University of British Columbia, Nova Scotia, Canada, E-mail: lammertynj@gmail.com

Received: 27-Sep-2024, Manuscript No. CSSB-24-34877; **Editor assigned:** 30-Sep-2024, PreQC No. CSSB-24-34877 (PQ); **Reviewed:** 14-Oct-2024, QC No. CSSB-24-34877; **Revised:** 21-Oct-2024, Manuscript No. CSSB-24-34877 (R); **Published:** 28-Oct-2024, DOI: 10.35248/2332-0737.24.12.100

Citation: Lammertyn J (2024). Parasite-Powered Brain Therapies: Genetic Engineering's Role in Treating Alzheimer's and Parkinson’s. J Curr Synth Syst Bio. 12:100.

The potential impact of this technology extends beyond just the medical community it could revolutionize the way we approach drug delivery and treatment for brain-related diseases. As scientists continue to refine this approach and address the challenges, genetically engineered parasites may soon become an essential tool in the fight against some of the most debilitating conditions known to humanity.